London South East were delighted to welcome Incanthera to our April Investor Webinar (6.04.2021), where Chairman Tim McCarthy and CEO Dr Simon Ward presented and took questions. Watch the full interview here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Every now and again, I reassess my investment in SNG.
Then I remember: a) £80m raised in the blink of an eye from II - not an easy feat. They would have done their due diligence and risk assessment. b) inclusion in Activ 2 - selected out of hundreds c) glowing Lancet review - repeated in Jan/Feb d) science behind interferon and Ace-2 e) More scientific focus on therapeutics f) more focus on interferons - and away from that unhelpful WHO report on intravenous interferon
There are a lot of unknowns; we can speculate (and argue!) about manufacturing capacity, unblinding due dates and RNS dates but these are the 'knowns'. Pretty good solid stuff, I reckon.
The company has allready stated that it plans to produce 100k doses from Jan 2020. They took shareholders money for this purpose in the fundraise. They also said that they planned to have 1m treatments by winter in the March19 fundraise. So if they are going to ramp up production they are ramping from that base.
"watch from 7 min 30 sec onward, immediately after the army he clearly says ramping is after data readout."
No he doesn't. There's no mention of ramping anything. His words are "there's a whole army of people working on the manufacturing side to make sure we can make enough drug to satisfy market demand".
Nothing about that suggests that they're waiting until they have the data before beginning the manufacturing they've already committed to. But if you're saying that it will eventually need scaling up again to take it beyond the 100,000/month target they've already set, I agree.
SNG raised funds to start manufacturing in January, before approval. Yet again, they have failed to deliver. If they are sure of success, and they told shareholders the purpose of the raise was to begin manufacturing why have they not started. Also, reducing the numbers of p3 saved £15million, they are not cash poor.
Scinv - You are spamming the board now with your drivel. Please stop it.
- The circular for the fund raise in Oct/Nov said £30m was for ramping up production. - Go and find the Sharesoc presentation in November as well. RM specifically stated that the aim was to get to 100,000 treatments (NOT doses) per month in EARLY 2021.
If they haven't started stocking up the shelves now, it sounds like they will be pretty soon.
The fact is, unless one of us works for Synairgen, none of us know for sure until the next update.
It IS reasonable to ask how much product we have and at some point i hope they'll tell us. The stated ambition after July 20th was 1 million doses by end of year. We know that half of the placing money was to ramp up production with Akron taking over. In the autumn Sharesoc RM said the ambition was 100k a month from January - in his most recent interview he said 10s if not 100s of thousands - again as an ambition - which felt slightly backtracky to some of us. We also know that they were starting P3 with Rentschler product but we don't know if Rentschler left anything in the cupboard or if it's affected by the dosing change. I agree with the posters who say that NIH would not start us on Activ-2 without a pretty solid gauge on our ability to supply immediately after EUA. Would be nice to know though.... On Activ-2 graduation we'll hear for sure.
I don't get the obsession with how many doses are on the shelf Scinv. How many units they can knock out post-EUA approval (or other approval milestone) would be far more important. If Eli Lilly could do come up with a manufacturing schedule for the FDA that they agree to, so can Synairgen. If I didn't think this had already been discussed at some level between the FDA and Synairgen and they were not happy to proceed on said basis, I wouldn't be invested here.
Talking of the last RM update......Take a look Scinv. From 4:10 hTTps://www.youtube.com/watch?v=nhFqeW6sIXg Not engaging further - you are not going to get actual evidence until the company announce it.
Fruits, dead right, I was trying to explain to the de-ramper to check out Activ-2 inclusion criteria but he is too hell bent on ignoring requests to do his research before he comments. Another child in the bin for me
Scinv , Eli-Lilly had production in progress before EAU, ( you can wade through the EL investor relations press releases and you will find figures there), so we can expect no less from any other Activ-2 candidate IMO. Can you think of any reason why the the FDA would put us on such a high-profile trial without knowing from the BOD that we can deliver on their estimated required numbers? Nor can I. If you are still not convinced, consider Polar Capital who will have done their own due diligence, including scale-up capability, far beyond what is discussed on this BB. Their increasing stake indicates no red flags to me.
Not to mention that bit in RM's last interview that said something along the lines of "multiple firms interested in the franchise". He wouldn't say something like that if he didn't know he already had other businesses showing great interest in us, and businesses wouldn't show interest in us if we couldn't prove good product manufacturing processes, or the ability to scale up production if needed. Now like a good stew, leave this to simmer and go out in the garden and enjoy the sun :)
Check Activ-2 Scinv, you will find all the answers you need there. I don't need to post links because we have all seen it, go and find it yourself, it might stop you subtly de-ramping this share for a change
Scinv...go back and re-watch any recent RM interviews eg Vox, Proactive etc. Way back on 18.11.20, RM stated 100,000 per month in 2021. Also, if you seriously believe the US Activ2 trial and Warp speed havent already adressed production in the light of a positive trial result - and EUA - where have you been for the last 9 months ? Biden could even use the Defense Production Act to seriosuly ramp up production with a SNG US partner if/when required.